Results 111 to 120 of about 11,937 (148)
Some of the next articles are maybe not open access.
Pharmacology of Leukotriene Receptor Antagonists
American Journal of Respiratory and Critical Care Medicine, 1998Abstract Preclinical pharmacological studies have demonstrated that cysLT1 receptor antagonists, such as zafirlukast, montelukast, and pobilukast, are potent and selective antagonists of cysteinyl leukotriene (cysLT) activity. In vitro, these agents compete with [3H]LTD4 for binding to cysLT1 receptors present on guinea pig and human ...
openaire +2 more sources
Leukotriene receptor antagonists - an update
Drug and Therapeutics Bulletin, 2005Montelukast (Singulair - MSD) and zafirlukast (Accolate - AstraZeneca) are oral leukotriene receptor antagonists, licensed for the treatment of patients with asthma. In 1998, soon after their launch, we concluded that there was insufficient evidence to clearly define their place in treatment.1 Here, we reconsider their role in adults and children with ...
openaire +2 more sources
Allergie et immunologie, 1999
Today, medicinal treatment of asthma over the long term is well codified and involves inhaled corticosteroid therapy, in association or not with beta 2-mimetic substances. Numerous studies have demonstrated the importance of leukotrienes in bronchoconstriction and in the delayed inflammatory reaction of asthma.
openaire +1 more source
Today, medicinal treatment of asthma over the long term is well codified and involves inhaled corticosteroid therapy, in association or not with beta 2-mimetic substances. Numerous studies have demonstrated the importance of leukotrienes in bronchoconstriction and in the delayed inflammatory reaction of asthma.
openaire +1 more source
New and promising type of leukotriene B4 (LTB4) antagonists based on the 1,4-benzodioxine structure
European Journal of Medicinal Chemistry, 2023Latifa Bouissane +2 more
exaly
Leukotriene antagonists in asthma
Journal of Paediatrics and Child Health, 2012openaire +2 more sources